skip to main content
Show Results with:

Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy

Warden, Bruce A. et al.

Journal of clinical lipidology. Volume 13:Number 4 (2019, July 20th); pp 580-585 -- Elsevier

Online access

  • Title:
    Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy
  • Author: Warden, Bruce A.;
    Minnier, Jessica;
    Watts, Gerald F.;
    Fazio, Sergio;
    Shapiro, Michael D.
  • Found In: Journal of clinical lipidology. Volume 13:Number 4 (2019, July 20th); pp 580-585
  • Journal Title: Journal of clinical lipidology
  • Subjects: Diabète--Périodiques; Hypertension artérielle--Périodiques; Lipides--Métabolisme, Troubles du--Périodiques; Obésité--Périodiques; Lipoproteins--drug effects--Periodicals; Lipids--Metabolism--Disorders--Periodicals; Lipids--Periodicals; Lipids; Lipids--Metabolism--Disorders; Periodicals; Lipoprotein(a)--Proprotein convertase subtilisin/kexin type 9 inhibitors--Niacin--Atherosclerotic cardiovascular disease--Pharmacotherapy; Electronic journals; Dewey: 616.3997005
  • Rights: Licensed
  • Publication Details: Elsevier
  • Abstract: Background Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein associated with atherosclerotic cardiovascular disease. Niacin and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) both lower Lp(a). Objective The objective of the study was to determine if addition of PCSK9i to background niacin therapy further lowers Lp(a). Methods This study is a retrospective analysis of patients who met the following inclusion criteria: initiated PCSK9i therapy, had Lp(a) measurements before and after initiation of PCSK9i, and for the combination therapy group, PCSK9i was added on top of baseline niacin monotherapy. Of the 150 patients included in this study, 136 were on monotherapy (PCSK9i) and 14 were on combination therapy (niacin + PCSK9i). Lp(a) values were assessed in both groups before and after the addition of PCSK9i. Results Median percent and absolute Lp(a) reductions in the niacin + PCSK9i combination therapy group were −15.3% (interquartile range [IQR] −31.8, −1) and −9 mg/dL (IQR −37.2, −0.5), respectively, from a baseline Lp(a) of 95 mg/dL (IQR 20.5, 171). These reductions were statistically significant or nearly so ( P  = .04 and P  = .05, respectively). Median percent and absolute Lp(a) reductions in the PCSK9i monotherapy group were −17.3% (IQR −34.4, 0) and −6 mg/dL (IQR −16, 0), respectively, from a baseline Lp(a) of 39.5 mg/dL (IQR 15, 117.5). There was no difference in median percent and absolute change in Lp(a) between monotherapy and combination therapy groups ( P  = .84 and P  = .54, respectively). Conclusions Our study demonstrates that the addition of PCSK9i to background of niacin therapy is associated with ∼15% reduction in Lp(a) beyond that achieved with background niacin monotherapy. Highlights Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein associated with atherosclerotic cardiovascular disease risk. Beyond use of niacin, there are limited therapeutic options for Lp(a) lowering. Addition of the proprotein convertase subtilisin/kexin type 9 inhibitor to niacin therapy was associated with ∼15% reduction in Lp(a).
  • Identifier: System Number: ETOCvdc_100088041965.0x000001; Journal ISSN: 1933-2874; 10.1016/j.jacl.2019.04.008
  • Publication Date: 2019
  • Physical Description: Electronic
  • Shelfmark(s): 4958.545500
  • UIN: ETOCvdc_100088041965.0x000001

Searching Remote Databases, Please Wait